Abstract Questcor Pharmaceuticals was founded after the merger between Cypros Pharmaceuticals Corporation and RiboGene Inc. The company then acquired Aventis Acthar Gel. To ascertain whether this company could be acquired by Embry Investment Group (EIG), the study undertook to review Questcor Pharmaceutical Inc. annual reports from the year 1996 to 2001. The study has nevertheless reviewed the company's 2012 third quarter financial results. The study showed that the company's share value was increasing from the time it was incorporated. Its gross profit was also on an upward trend from 1996. This makes the company suitable for acquisition by Embry Investment Group.
Executive Summary The first section of this report, introduction, highlights the general background of the company with emphasis laid on the company's history; mission and business strategy; the management team; board of directors; corporate responsibility; and code of ethics. The second section dwells on the methodology used in conducting this study which is basically about conducting reviews on the company's annual reports from the year 1996 to 2001. Financial statements for the third quarter of the year 2012 were also brought into perspective. It was finally established that EIG could actually acquire the company because it had shown prospects of growth.
Introduction Embry Investment Group (EIG) seeks to analyze a company and make recommendations on whether or not it